This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The Macular Photocoagulation Study (MPS) is a multicenter clinical trial that evaluates argon laser photocoagulation for eyes with choroidal neovascular membranes. The question to be answered is, does coagulating a leaking vessel outside the fovea prevent significant loss of visual acuity. The study is being funded by the National Eye Institute.
Patients with suitable macular lesions can be enrolled in the study if they have macular degeneration, ocular histoplasmosis, or idiopathic choroidal neovascularization. The eligibility criteria for the MPS are as follows: (1) ophthalmoscopic evidence of macular degeneration, histoplasmosis, or idiopathic choroidal neovascularization; (2) angiographic evidence of choroidal neovascularization outside the fovea; (3) visual acuity of 20/100 or better in the eye to be entered; and (4) willingness of the patient to have the eye randomly assigned to argon laser photocoagulation or to no treatment.
Patients who agree to participate will be randomly assigned to argon laser photocoagulation or to
Fine SL. Macular Photocoagulation Study. Arch Ophthalmol. 1980;98(5):832. doi:10.1001/archopht.1980.01020030826002
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: